{{NoteTA|G1=ME}}
{{Infobox drug
| Verifiedfields =
| verifiedrevid  =
| image = Covaxin.jpg
| caption =BBV152針劑
| type = vaccine
| target = [[严重急性呼吸系统综合征冠状病毒2|SARS-CoV-2]]
| vaccine_type = Inactivated
| tradename = Covaxin
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category =
| routes_of_administration = [[肌肉注射|肌肉注射]]
| ATC_prefix =  None <!-- scheduled to be J07BX03 in 2022 -->
| ATC_suffix =
| ATC_supplemental  =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =
| legal_US =
| legal_US_comment =
| legal_status =緊急使用許可 :<br />[[印度|印度]]<ref name="NYT India">{{Cite news|title=India Approves Oxford-AstraZeneca Covid-19 Vaccine and 1 Other|url=https://www.nytimes.com/2021/01/03/world/asia/india-covid-19-vaccine.html|newspaper=The New York Times|date=2021-01-03|accessdate=2021-05-09|issn=0362-4331|language=en-US|first=Emily|last=Schmall|first2=Sameer|last2=Yasir|archive-date=2021-01-09|archive-url=https://web.archive.org/web/20210109040401/https://www.nytimes.com/2021/01/03/world/asia/india-covid-19-vaccine.html|dead-url=no}}</ref><br />[[伊朗|伊朗]]<ref name="IRNA Iran">{{Cite web|title=Iran issues permit for emergency use for three other COVID-19 vaccines: Official|url=https://en.irna.ir/news/84233593/Iran-issues-permit-for-emergency-use-for-three-other-COVID-19|access-date=2021-05-09|date=2021-02-17|work=IRNA English|language=en|archive-date=2021-02-27|archive-url=https://web.archive.org/web/20210227144527/https://en.irna.ir/news/84233593/Iran-issues-permit-for-emergency-use-for-three-other-COVID-19|dead-url=no}}</ref><br />[[辛巴威|辛巴威]]<ref name="HT Zimbabwe">{{Cite web|title=Zimbabwe approves Covaxin, first in Africa to okay India-made Covid-19 vaccine|url=https://www.hindustantimes.com/world-news/zimbabwe-approves-covaxin-first-in-africa-to-okay-india-made-covid-19-vaccine-101614859597880.html|access-date=2021-05-09|date=2021-03-04|work=Hindustan Times|language=en|archive-date=2021-03-05|archive-url=https://web.archive.org/web/20210305231730/https://www.hindustantimes.com/world-news/zimbabwe-approves-covaxin-first-in-africa-to-okay-india-made-covid-19-vaccine-101614859597880.html|dead-url=no}}</ref><br />[[毛里求斯|模里西斯]]<ref name="BB Mauritius">{{Cite web|title=Dr Jagutpal: «Une cargaison de 200 000 vaccins Covaxin débarque demain»|url=https://www.lexpress.mu/article/390493/dr-jagutpal-une-cargaison-200-000-vaccins-covaxin-debarque-demain|access-date=2021-05-09|date=2021-03-18|last=Rédaction|first=La|work=lexpress.mu|language=fr|archive-date=2021-04-21|archive-url=https://web.archive.org/web/20210421020152/https://www.lexpress.mu/article/390493/dr-jagutpal-une-cargaison-200-000-vaccins-covaxin-debarque-demain|dead-url=no}}</ref><br />[[尼泊尔|尼泊爾]]<ref name="covax-nep">{{Cite news|title=Nepal becomes third country to give emergency nod to Indian vaccine COVAXIN|url=https://www.reuters.com/article/health-coronavirus-nepal-india-idUSKBN2BB1KN|newspaper=Reuters|date=2021-03-19|accessdate=2021-05-09|language=en|first=Gopal|last=Sharma|archive-date=2021-04-25|archive-url=https://web.archive.org/web/20210425025838/https://www.reuters.com/article/health-coronavirus-nepal-india-idUSKBN2BB1KN|dead-url=no}}</ref><br />[[巴拉圭|巴拉圭]]<ref name="covaxin-py">{{Cite web|title=Covid-19: India provides 100,000 doses of Covaxin vaccine to Paraguay|url=https://www.hindustantimes.com/india-news/covid19-india-provides-100-000-doses-of-covaxin-vaccine-to-paraguay-101617057324587.html|access-date=2021-05-09|date=2021-03-30|work=Hindustan Times|language=en|archive-date=2021-05-04|archive-url=https://web.archive.org/web/20210504124950/https://www.hindustantimes.com/india-news/covid19-india-provides-100-000-doses-of-covaxin-vaccine-to-paraguay-101617057324587.html|dead-url=no}}</ref><br />[[墨西哥|墨西哥]]<ref name=“covaxin-mx”/><br />[[世界卫生组织|世界卫生组织]]
| CAS_number_Ref     = 
| CAS_number         = 
| DrugBank_Ref       = 
| UNII               = 76JZE5DSN6
| DrugBank           = DB15847
| PubChem            = 
| ChemSpiderID_Ref   = 
| ChemSpiderID       = 
}}

'''科瓦克辛'''（Covaxin，代號為'''BBV152'''），是[[印度|印度]]的一款針對2019冠状病毒病的[[灭活疫苗|灭活]][[2019冠状病毒病疫苗|疫苗]]，由{{link-en|巴拉特生物技術公司|Bharat Biotech}}和{{link-en|印度醫學研究理事會|Indian Council of Medical Research}}合作完成，科瓦克辛已於2021年11月3日獲[[世衛組織|世衛組織]]發出緊急使用授權<ref name="WHO_News_COVAXIN">{{cite news |title=印度新冠疫苗“科瓦克辛”获得世卫组织批准 |url=https://news.un.org/zh/story/2021/11/1093862 |accessdate=2021-11-28 |work=联合国新闻 |date=2021-11-03 |archive-date=2021-11-28 |archive-url=https://web.archive.org/web/20211128084828/https://news.un.org/zh/story/2021/11/1093862 |dead-url=no }}</ref>。

==臨床測試==
===第一及第二階段===
2020年5月，印度醫學研究理事會（ICMR）{{link-en|國家病毒學研究所|National Institute of Virology}}批准，並提供了用於開發由自己國家發明的[[2019冠状病毒病疫苗|2019冠状病毒病疫苗]]<ref>{{cite news|title=ICMR teams up with Bharat Biotech to develop Covid-19 vaccine|url=https://www.livemint.com/news/india/icmr-teams-up-with-bharat-biotech-to-develop-covid-19-vaccine-11589038719666.html|work=Livemint|date=2020-05-09|language=en|accessdate=2021-04-02|archive-date=2021-05-03|archive-url=https://web.archive.org/web/20210503071056/https://www.livemint.com/news/india/icmr-teams-up-with-bharat-biotech-to-develop-covid-19-vaccine-11589038719666.html|dead-url=no}}</ref><ref>{{cite news|vauthors=Chakrabarti A|title=India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech|url=https://theprint.in/health/india-to-develop-fully-indigenous-covid-vaccine-as-icmr-partners-with-bharat-biotech/418180/|work=ThePrint|date=2020-05-10|accessdate=2021-04-02|archive-date=2021-05-03|archive-url=https://web.archive.org/web/20210503084559/https://theprint.in/health/india-to-develop-fully-indigenous-covid-vaccine-as-icmr-partners-with-bharat-biotech/418180/|dead-url=no}}</ref>。2020年6月，印度藥品管理局（DCGI）批准疫苗進入第一及第二階段的人體[[臨床測試|臨床測試]]，並取名為科瓦克辛（Covaxin）<ref>{{cite news|title=India's First COVID-19 Vaccine Candidate Approved for Human Trials|url=https://www.nytimes.com/reuters/2020/06/29/world/asia/29reuters-health-coronavirus-india-vaccine.html|work=The New York Times|date=2020-06-29|accessdate=2021-04-02|archive-date=2021-02-13|archive-url=https://web.archive.org/web/20210213041617/https://www.nytimes.com/reuters/2020/06/29/world/asia/29reuters-health-coronavirus-india-vaccine.html|dead-url=no}}</ref>。印度醫學研究理事會的第一及第二階段的人體臨床測試中共有十二個地點，並對疫苗進行臨床測試的人進行雙盲和安慰劑對照<ref>{{cite news|title=Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS|url=http://ddnews.gov.in/health/human-clinical-trials-potential-covid-19-vaccine-%E2%80%98covaxin%E2%80%99-started-aiims|work=DD News|publisher=Prasar Bharati, Ministry of I & B, Government of India|date=2020-07-25|accessdate=2021-04-02|archive-date=2021-01-24|archive-url=https://web.archive.org/web/20210124153146/http://ddnews.gov.in/health/human-clinical-trials-potential-covid-19-vaccine-%E2%80%98covaxin%E2%80%99-started-aiims|dead-url=no}}</ref><ref>{{cite news|last1=Press|first1=Associated|title=Asia Today: Amid new surge, India tests potential vaccine|url=https://www.washingtonpost.com/business/asia-today-skorea-records-113-new-cases-most-from-overseas/2020/07/24/21f23ad0-ce17-11ea-99b0-8426e26d203b_story.html|access-date=2020-12-17|work=Washington Post|date=2020-07-25|archive-date=2021-02-16|archive-url=https://web.archive.org/web/20210216032455/https://www.washingtonpost.com/business/asia-today-skorea-records-113-new-cases-most-from-overseas/2020/07/24/21f23ad0-ce17-11ea-99b0-8426e26d203b_story.html|dead-url=no}}</ref><ref>{{cite news|title=Delhi: 30-year-old is first to get dose of trial drug Covaxin|url=https://indianexpress.com/article/india/aiims-administers-first-dose-of-bharat-biotechs-potential-covid-vaccine-to-30-yr-old-man-6521778/|work=The Indian Express|date=2020-07-25|language=en|accessdate=2021-04-02|archive-date=2021-03-16|archive-url=https://web.archive.org/web/20210316225319/https://indianexpress.com/article/india/aiims-administers-first-dose-of-bharat-biotechs-potential-covid-vaccine-to-30-yr-old-man-6521778/|dead-url=no}}</ref>。

2020年12月，該公司宣布了階段試驗的報告，並通過[[MedRxiv|MedRxiv]]提出了結果<ref>{{cite news|last1=Perappadan|first1=Bindu Shajan|title=Coronavirus {{!}} Covaxin phase-1 trial results show promising results|url=https://www.thehindu.com/sci-tech/science/coronavirus-covaxin-phase-1-trial-results-show-vaccine-is-safe/article33348040.ece|access-date=2020-12-17|work=The Hindu|date=2020-12-16|language=en|archive-date=2020-12-17|archive-url=https://web.archive.org/web/20201217020211/https://www.thehindu.com/sci-tech/science/coronavirus-covaxin-phase-1-trial-results-show-vaccine-is-safe/article33348040.ece|dead-url=no}}</ref><ref>{{cite news|last1=Sabarwal|first1=Harshit|title=Covaxin's phase 1 trial result shows robust immune response, mild adverse events|url=https://www.hindustantimes.com/india-news/covaxin-s-phase-1-trial-result-shows-robust-immune-response-mild-adverse-events/story-0swYxDQsyoK5POHjjPO22M.html|access-date=2020-12-17|work=Hindustan Times|date=2020-12-16|language=en|archive-date=2020-12-16|archive-url=https://web.archive.org/web/20201216172146/https://www.hindustantimes.com/india-news/covaxin-s-phase-1-trial-result-shows-robust-immune-response-mild-adverse-events/story-0swYxDQsyoK5POHjjPO22M.html|dead-url=yes}}</ref>，該報告後來在《[[柳葉刀_(雜誌)|柳葉刀]]》中發表<ref>{{Cite journal|title=Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial|url=https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30942-7/abstract|last=Ella|first=Raches|last2=Vadrevu|first2=Krishna Mohan|date=2021-05-01|journal=The Lancet Infectious Diseases|issue=5|doi=10.1016/S1473-3099(20)30942-7|volume=21|pages=637–646|language=en|issn=1473-3099|pmid=33485468|last3=Jogdand|first3=Harsh|last4=Prasad|first4=Sai|last5=Reddy|first5=Siddharth|last6=Sarangi|first6=Vamshi|last7=Ganneru|first7=Brunda|last8=Sapkal|first8=Gajanan|last9=Yadav|first9=Pragya}}</ref>。

2021年3月8日，第二階段結果發表於《柳葉刀》。該研究表明，第二期試驗具有更高的免疫反應和引起的[[T細胞|T細胞]]反應。由於第一階段對比的給藥方案的差異，一般在第一階段完成後的的2週內給出的第二階段的劑量，在4週內給出，而不是在第一階段完成後的的2週內給出。結果顯示第二階段的疫苗的響應顯著上升<ref name="auto">{{Cite journal|title=Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial|url=https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00070-0/abstract|last=Ella|first=Raches|last2=Reddy|first2=Siddharth|date=2021-03-08|journal=The Lancet Infectious Diseases|issue=0|doi=10.1016/S1473-3099(21)00070-0|volume=0|language=en|issn=1473-3099|pmid=33705727|last3=Jogdand|first3=Harsh|last4=Sarangi|first4=Vamshi|last5=Ganneru|first5=Brunda|last6=Prasad|first6=Sai|last7=Das|first7=Dipankar|last8=Raju|first8=Dugyala|last9=Praturi|first9=Usha}}</ref>。

===第三階段===
2020年11月，科瓦克辛疫苗在完成第一和第二階段段後<ref>{{Cite journal|title=Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion InactivatedSARS-CoV-2 Vaccine - BBV152|url=http://biorxiv.org/lookup/doi/10.1101/2020.09.09.285445|last=Ganneru|first=Brunda|last2=Jogdand|first2=Harsh|date=2020-09-09|doi=10.1101/2020.09.09.285445|language=en|last3=Dharam|first3=Vijaya Kumar|last4=Molugu|first4=Narasimha Reddy|last5=Prasad|first5=Sai D|last6=Vellimudu|first6=Srinivas|last7=Ella|first7=Krishna M|last8=Ravikrishnan|first8=Rajaram|last9=Awasthi|first9=Amit}}</ref>，批准進行第三階段人類試驗<ref>{{cite news|title=Coronavirus {{!}} Covaxin Phase III trial from November|url=https://www.thehindu.com/business/covaxin-phase-iii-trial-from-november/article32928549.ece|work=The Hindu|date=2020-10-23|language=en|accessdate=2021-04-02|archive-date=2021-01-26|archive-url=https://web.archive.org/web/20210126191214/https://www.thehindu.com/business/covaxin-phase-iii-trial-from-november/article32928549.ece|dead-url=no}}</ref>。該試驗涉及在18歲及以上年齡組的隨機志願者，並於11月25日開始雙盲、安慰劑對照研究<ref>{{Cite web|title=An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers|url=https://clinicaltrials.gov/ct2/show/NCT04641481|access-date=2020-11-26|website=clinicaltrials.gov|publisher=[[United_States_National_Library_of_Medicine|United States National Library of Medicine]]|type=Registry|id=NCT04641481|archive-date=2020-11-26|archive-url=https://web.archive.org/web/20201126061700/https://clinicaltrials.gov/ct2/show/NCT04641481|dead-url=no}}</ref>。第三階段涉及來自印度的大約26,000名志願者<ref>{{cite news|title=Bharat Biotech begins Covaxin Phase III trials|url=https://indianexpress.com/article/india/bharat-biotech-begins-covaxin-phase-iii-trials-7055237/|work=The Indian Express|date=2020-11-18|language=en|accessdate=2021-04-02|archive-date=2021-01-22|archive-url=https://web.archive.org/web/20210122061216/https://indianexpress.com/article/india/bharat-biotech-begins-covaxin-phase-iii-trials-7055237/|dead-url=no}}</ref>。第三階段試驗共涵蓋了該國的幾個州 ,共22個地點，包括[[德里|德里]]，[[卡納塔克|卡納塔克]]和[[西孟加拉邦|西孟加拉邦]]<ref>{{cite news|vauthors=Sen M|title=List of states that have started phase 3 trials of India's first Covid vaccine|url=https://www.livemint.com/news/india/coronavirus-vaccine-in-india-these-states-have-started-phase-3-trials-of-bharat-biotech-covaxin-11606908773897.html|work=mint|date=2020-12-02|language=en|accessdate=2021-04-02|archive-date=2021-02-13|archive-url=https://web.archive.org/web/20210213035514/https://www.livemint.com/news/india/coronavirus-vaccine-in-india-these-states-have-started-phase-3-trials-of-bharat-biotech-covaxin-11606908773897.html|dead-url=no}}</ref>。第三階段驗的拒絕率遠高於第一和第二階段。因此，12月22日僅招募了13,000名志願者，而1月5日的人數增加到23,000人<ref name="ndtv-phase3-drop">{{cite news|url=https://www.ndtv.com/india-news/coronavirus-news-70-80-drop-in-participation-for-phase-3-trials-of-covaxin-official-2340001|work=NDTV|date=2020-12-17|title=70%-80% Drop In Participation For Phase 3 Trials Of Covaxin: Official|accessdate=2021-04-02|archive-date=2020-12-17|archive-url=https://web.archive.org/web/20201217183454/https://www.ndtv.com/india-news/coronavirus-news-70-80-drop-in-participation-for-phase-3-trials-of-covaxin-official-2340001|dead-url=no}}</ref><ref name="print-incomplete-approval">{{cite news|url=https://theprint.in/health/bharat-biotechs-covaxin-given-conditional-nod-based-on-incomplete-phase-3-trial-results-data/578389/|title=Bharat Biotech's Covaxin given conditional nod based on incomplete Phase 3 trial results data|work=The Print|date=2021-01-03|accessdate=2021-04-02|archive-date=2021-03-01|archive-url=https://web.archive.org/web/20210301063655/https://theprint.in/health/bharat-biotechs-covaxin-given-conditional-nod-based-on-incomplete-phase-3-trial-results-data/578389/|dead-url=no}}</ref>。

截至2021年3月，第三階段的結果臨時療效率為81％<ref name="auto" /><ref>{{cite news|last1=Kumar|first1=N. Ravi|title=Bharat Biotech says COVID-19 vaccine Covaxin shows 81% efficacy in Phase 3 clinical trials|url=https://www.thehindu.com/sci-tech/health/bharat-biotech-says-covid-19-vaccine-shows-81-interim-efficacy/article33980224.ece|work=The Hindu|date=2021-03-03|language=en|accessdate=2021-04-02|archive-date=2021-04-16|archive-url=https://web.archive.org/web/20210416105455/https://www.thehindu.com/sci-tech/health/bharat-biotech-says-covid-19-vaccine-shows-81-interim-efficacy/article33980224.ece|dead-url=no}}</ref>。

===B.1.1.7 變種病毒===
2020年12月，在英國確定了一個新的[[严重急性呼吸综合征冠状病毒2变种|严重急性呼吸综合征冠状病毒2变种]][[B.1.1.7譜系|B.1.1.7譜系]]（VOC-202012/01，又稱Alpha譜系）<ref>{{Cite news|title=Inside the B.1.1.7 Coronavirus Variant|url=https://www.nytimes.com/interactive/2021/health/coronavirus-mutations-B117-variant.html|newspaper=The New York Times|date=2021-01-18|accessdate=2021-05-09|issn=0362-4331|language=en-US|first=Jonathan|last=Corum|first2=Carl|last2=Zimmer|archive-date=2021-01-20|archive-url=https://web.archive.org/web/20210120143819/https://www.nytimes.com/interactive/2021/health/coronavirus-mutations-B117-variant.html|dead-url=no}}</ref>。透過對該變種病毒的研究，並在[[bioRxiv|bioRxiv]]中發出的初步結果表明，科瓦克辛疫苗對該變種病毒有效<ref>{{Cite journal|title=Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum|url=http://biorxiv.org/lookup/doi/10.1101/2021.01.26.426986|last=Sapkal|first=Gajanan N.|last2=Yadav|first2=Pragya D.|date=2021-01-26|doi=10.1101/2021.01.26.426986|language=en|last3=Ella|first3=Raches|last4=Deshpande|first4=Gururaj R.|last5=Sahay|first5=Rima R.|last6=Gupta|first6=Nivedita|last7=Mohan|first7=V Krishna|last8=Abraham|first8=Priya|last9=Panda|first9=Samiran}}</ref>。

==製造商==
疫苗用巴拉特生物技術公司內部的[[Vero細胞|Vero細胞]]製造生產<ref>{{Cite journal|title=Enhancing viral vaccine production using engineered knockout vero cell lines – A second look|url=https://linkinghub.elsevier.com/retrieve/pii/S0264410X18303463|last=Hoeksema|first=F.|last2=Karpilow|first2=J.|date=2018-04-XX|journal=Vaccine|issue=16|doi=10.1016/j.vaccine.2018.03.010|volume=36|pages=2093–2103|language=en|pmc=PMC5890396|pmid=29555218|last3=Luitjens|first3=A.|last4=Lagerwerf|first4=F.|last5=Havenga|first5=M.|last6=Groothuizen|first6=M.|last7=Gillissen|first7=G.|last8=Lemckert|first8=A.A.C.|last9=Jiang|first9=B.}}</ref>，具有提供約3000萬劑的能力<ref>{{cite news|title=Coronavirus vaccine update: Bharat Biotech's Covaxin launch likely in Q2 of 2021, no word on pricing yet|url=https://www.businesstoday.in/sectors/pharma/coronavirus-vaccine-update-bharat-biotech-covaxin-launch-likely-in-q2-of-2021-no-word-on-pricing-yet/story/422659.html|access-date=2020-12-13|work=www.businesstoday.in|agency=India Today Group|archive-date=2020-12-11|archive-url=https://web.archive.org/web/20201211204753/https://www.businesstoday.in/sectors/pharma/coronavirus-vaccine-update-bharat-biotech-covaxin-launch-likely-in-q2-of-2021-no-word-on-pricing-yet/story/422659.html|dead-url=no}}</ref>。該公司正在印度泰倫迦納邦海得拉巴在其基因谷中設立第二個工廠來製造科瓦克辛疫苗。該公司與如[[奥里萨邦|奥里萨邦]]的其他州政府談判<ref>{{cite news|title=Odisha fast tracks coronavirus vaccine manufacturing unit|url=https://www.newindianexpress.com/states/odisha/2020/nov/07/odisha-fast-tracks-coronavirus-vaccine-manufacturing-unit-2220523.html|work=The New Indian Express|date=2020-11-07|accessdate=2021-04-03|archive-date=2021-01-22|archive-url=https://web.archive.org/web/20210122042810/https://www.newindianexpress.com/states/odisha/2020/nov/07/odisha-fast-tracks-coronavirus-vaccine-manufacturing-unit-2220523.html|dead-url=no}}</ref>，為國家製作疫苗。除此之外，它們還發展了科瓦克辛疫苗與全球的合作<ref>{{cite news|vauthors=Raghavan P|title=Bharat Biotech exploring global tie-ups for Covaxin manufacturing|url=https://indianexpress.com/article/coronavirus/bharat-biotech-exploring-global-tie-ups-for-covaxin-manufacturing-6608429/|work=The Indian Express|date=2020-09-24|language=en|accessdate=2021-04-03|archive-date=2021-01-22|archive-url=https://web.archive.org/web/20210122042542/https://indianexpress.com/article/coronavirus/bharat-biotech-exploring-global-tie-ups-for-covaxin-manufacturing-6608429/|dead-url=no}}</ref>。

2020年12月，Ocugen, Inc.與巴拉特生物技術公司合作，共同為科瓦克辛疫苗開發美國市場<ref>{{Cite news|author=Reuters Staff|date=2020-12-22|title=Ocugen to co-develop Bharat Biotech's COVID-19 vaccine candidate for U.S.|language=en|work=Reuters|url=https://www.reuters.com/article/health-coronavirus-ocugen-bharat-idUSKBN28W1G4|access-date=2021-01-05|archive-date=2020-12-26|archive-url=https://web.archive.org/web/20201226043347/https://www.reuters.com/article/health-coronavirus-ocugen-bharat-idUSKBN28W1G4|dead-url=no}}</ref><ref>{{Cite news|title=Bharat Biotech, Ocugen to co-develop Covaxin for US market|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-ocugen-to-co-develop-covaxin-for-us-market/articleshow/79872249.cms?from=mdr|access-date=2021-01-05|archive-date=2021-07-05|archive-url=https://web.archive.org/web/20210705191705/https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-ocugen-to-co-develop-covaxin-for-us-market/articleshow/79872249.cms?from=mdr|dead-url=no}}</ref>。2021年1月，精準藥物（{{lang|es|precisa medicamentos}}）與巴拉特生物技術公司達成協議，在巴西提供科瓦克辛疫苗<ref>{{cite news|title=Bharat Biotech inks pact with Precisa Med to supply Covaxin to Brazil|url=https://www.livemint.com/news/india/bharat-biotech-inks-pact-with-precisa-med-to-supply-covaxin-to-brazil-11610456928074.html|work=mint|date=2021-01-12|language=en|accessdate=2021-04-03|archive-date=2021-03-29|archive-url=https://web.archive.org/web/20210329143637/https://www.livemint.com/news/india/bharat-biotech-inks-pact-with-precisa-med-to-supply-covaxin-to-brazil-11610456928074.html|dead-url=no}}</ref>。

==緊急使用授權==
{{see also|2019冠状病毒病疫苗}}
巴拉特生物技術公司向申請印度藥品管理局（DCGI）和印度政府申請緊急使用授權<ref>{{cite news|vauthors=Ghosh N|title=Bharat Biotech seeks emergency use authorization for Covid-19 vaccine|url=https://www.hindustantimes.com/india-news/bharat-biotech-seeks-emergency-use-authorization-for-covid-19-vaccine-govt-source/story-HmmD0JnniJeigdF6xmjxBO.html|work=Hindustan Times|date=2020-12-07|language=en|accessdate=2021-04-07|archive-date=2020-12-24|archive-url=https://web.archive.org/web/20201224121817/https://www.hindustantimes.com/india-news/bharat-biotech-seeks-emergency-use-authorization-for-covid-19-vaccine-govt-source/story-HmmD0JnniJeigdF6xmjxBO.html|dead-url=no}}</ref>。科瓦克辛（Covaxin）是繼[[印度血清研究所|印度血清研究所]]的印度版[[阿斯利康疫苗|阿斯利康疫苗]]（Covishield）、[[輝瑞|輝瑞]]和[[BioNTech|BioNTech]]合作研發的[[輝瑞疫苗|輝瑞疫苗]]之後，第三種獲印度政府批核緊急使用權的新型冠狀病毒病預防疫苗<ref>{{cite news|title=Coronavirus {{!}} After SII, Bharat Biotech seeks DCGI approval for Covaxin|url=https://www.thehindu.com/sci-tech/health/coronavirus-serum-institute-seeks-emergency-use-approval-for-covishield-in-india/article33265921.ece|work=The Hindu|date=2020-12-07|language=en|accessdate=2021-04-07|archive-date=2020-12-24|archive-url=https://web.archive.org/web/20201224142443/https://www.thehindu.com/sci-tech/health/coronavirus-serum-institute-seeks-emergency-use-approval-for-covishield-in-india/article33265921.ece|dead-url=no}}</ref>。

2021年1月2日，{{link-en|中央藥物標準控制組織|Central Drugs Standard Control Organisation}}（CDSCO）建議申獲得緊急使用權的許可<ref name="rec">{{cite news|title=Expert panel recommends granting approval for restricted emergency use of Bharat Biotech's Covaxin|url=https://indianexpress.com/article/india/bharat-biotechs-covaxin-covid-vaccine-approval-cdsco-7130213/|work=The Indian Express|date=2021-01-02|language=en|accessdate=2021-04-07|archive-date=2021-01-26|archive-url=https://web.archive.org/web/20210126074534/https://indianexpress.com/article/india/bharat-biotechs-covaxin-covid-vaccine-approval-cdsco-7130213/|dead-url=no}}</ref>，並於1月3日授予<ref>{{Cite news|date=2021-01-03|title=Coronavirus: India approves vaccines from Bharat Biotech and Oxford/AstraZeneca|language=en-GB|work=BBC News|url=https://www.bbc.com/news/world-asia-india-55520658|access-date=2021-01-03|archive-date=2021-01-03|archive-url=https://web.archive.org/web/20210103071943/https://www.bbc.com/news/world-asia-india-55520658|dead-url=no}}</ref>。因在第三階段測試數據發布之前給出了緊急批准，所以在一些媒體中受到批評<ref>{{cite web|title=Disputes Mount, but Heedless Govt Intent on Rolling Vaccine Candidates Out|url=https://science.thewire.in/health/covaxin-covishield-indian-government-rollout-peoples-hospital-phase-3-clinical-trials-centralisation-pm-cares/|date=2021-01-12|work=The Wire|access-date=2021-04-07|archive-date=2021-01-28|archive-url=https://web.archive.org/web/20210128163809/https://science.thewire.in/health/covaxin-covishield-indian-government-rollout-peoples-hospital-phase-3-clinical-trials-centralisation-pm-cares/|dead-url=no}}</ref><ref>{{cite news|title=AIPSN urges govt to reconsider emergency approval for Covaxin till Phase 3 data is published - Health News , Firstpost|url=https://www.firstpost.com/health/aipsn-urges-govt-to-reconsider-emergency-approval-for-covaxin-till-phase-3-data-is-published-9183481.html|work=Firstpost|date=2021-01-08|accessdate=2021-04-07|archive-date=2021-04-16|archive-url=https://web.archive.org/web/20210416120605/https://www.firstpost.com/health/aipsn-urges-govt-to-reconsider-emergency-approval-for-covaxin-till-phase-3-data-is-published-9183481.html|dead-url=no}}</ref>。

[[伊朗|伊朗]]和[[辛巴威|辛巴威]]批准緊急使用科瓦克辛疫苗<ref name="IRNA Iran"/><ref name="HT Zimbabwe" />。2021年3月18日，[[模里西斯|模里西斯]]收到了首次科瓦克辛疫苗的供應<ref name="BB Mauritius"/>。2021年3月19日，[[尼泊爾|尼泊爾]]於也授予科瓦克辛疫苗緊急使用權<ref name="covax-nep"/>。2021年3月29日，[[巴拉圭|巴拉圭]]收到100,000劑的科瓦克辛疫苗<ref name="covax-nep"/>。2021年4月7日，[[墨西哥|墨西哥]]對科瓦克辛疫苗發出緊急使用授權<ref name="“covaxin-mx”">{{Cite news|last=Staff|first=Reuters|date=2021-04-07|title=Mexico authorizes emergency use of Indian COVID-19 vaccine|language=en|work=Reuters|url=https://www.reuters.com/article/health-coronavirus-mexico-india-idUSKBN2BU04N|access-date=2021-04-07|archive-date=2021-04-07|archive-url=https://web.archive.org/web/20210407020124/https://www.reuters.com/article/health-coronavirus-mexico-india-idUSKBN2BU04N|dead-url=no}}</ref>。

2021年11月3日，印度國產疫苗科瓦克辛（Covaxin）獲[[世衛組織|世衛組織]]緊急授權，根據臨床試驗第3期，保護力達78%，是第七款由世衛組織發出緊急使用授權的新型冠狀病毒病預防疫苗<ref>{{Cite web|title=印度國產疫苗「Covaxin」獲WHO緊急授權　重症保護力達78%|url=https://www.ettoday.net/amp/amp_news.php7?news_id=2116054|date=2021-11-04|newspaper=ETtoday 新聞雲|access-date=2021-11-03|archive-date=2021-11-29|archive-url=https://web.archive.org/web/20211129161220/https://www.ettoday.net/amp/amp_news.php7?news_id=2116054|dead-url=no}}</ref><ref>{{Cite web|title=Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19|url=https://apps.who.int/iris/rest/bitstreams/1383483/retrieve|date=2021-11-03|website=WHO|access-date=2021-11-04|archive-date=2021-11-04|archive-url=https://web.archive.org/web/20211104022250/https://apps.who.int/iris/rest/bitstreams/1383483/retrieve|dead-url=no}}</ref>。

==參考文獻==
{{reflist|25em}}

{{COVID-19}}
{{疫苗}}
[[Category:2019冠状病毒病疫苗|Category:2019冠状病毒病疫苗]]
[[Category:2021年面世的產品|Category:2021年面世的產品]]
[[Category:印度發明|Category:印度發明]]
[[Category:灭活疫苗|Category:灭活疫苗]]